EQT X to Acquire Adalvo (B2B Generic Drug Dossiers)

July 18, 2025

EQT X (EQT) has agreed to acquire a majority stake in Adalvo, an asset-light B2B dossier developer that produces market-approval-ready generic drug dossiers for pharmaceutical companies. Existing shareholders, including Aztiq (holding company of Chairman Róbert Wessman), will reinvest part of their holdings and retain minority ownership. The deal is subject to customary approvals and is expected to close in H2 2025.

Buyers
EQT X
Targets
Adalvo
Sellers
Aztiq
Location
Malta
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.